Fate Therapeutics, Inc. (FATE)
After hours:
| Previous close | 2.9400 |
| Open | 2.9600 |
| Bid | 3.0700 x 300 |
| Ask | 3.1200 x 100 |
| Day's range | 2.9250 - 3.1000 |
| 52-week range | 1.6300 - 8.8300 |
| Volume | |
| Avg. volume | 1,592,951 |
| Market cap | 351.883M |
| Beta (5Y monthly) | 1.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7000 |
| Earnings date | 06 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.58 |
GlobeNewswireFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2024 the Company granted restricted stock units (RSUs) representing 16,400 shares of its common stock to two newly-hired non-executive employees. The grants were appro
- GlobeNewswire
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 12:45 PM ET in New York, New York. A live webcast, if recorded, of the p
ZacksWhy Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
